TIAA CREF Investment Management LLC cut its position in shares of Halyard Health Inc (NYSE:HYH) by 11.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 208,014 shares of the medical instruments supplier’s stock after selling 26,570 shares during the period. TIAA CREF Investment Management LLC’s holdings in Halyard Health were worth $9,606,000 at the end of the most recent reporting period.
Other hedge funds have also recently modified their holdings of the company. Jane Street Group LLC acquired a new position in shares of Halyard Health during the 3rd quarter valued at $211,000. Ramsey Quantitative Systems acquired a new position in shares of Halyard Health during the 4th quarter valued at $266,000. Koch Industries Inc. acquired a new position in shares of Halyard Health during the 4th quarter valued at $326,000. ING Groep NV increased its position in shares of Halyard Health by 23.2% during the 4th quarter. ING Groep NV now owns 7,060 shares of the medical instruments supplier’s stock valued at $326,000 after purchasing an additional 1,329 shares during the period. Finally, Suntrust Banks Inc. acquired a new position in shares of Halyard Health during the 4th quarter valued at $330,000. Institutional investors own 91.32% of the company’s stock.
Shares of NYSE HYH opened at $46.12 on Monday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.74 and a current ratio of 2.98. The firm has a market capitalization of $2,163.95, a P/E ratio of 19.63, a P/E/G ratio of 5.40 and a beta of 1.62. Halyard Health Inc has a 52-week low of $35.24 and a 52-week high of $50.99.
Halyard Health (NYSE:HYH) last issued its earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.23. The business had revenue of $428.10 million for the quarter, compared to analysts’ expectations of $413.94 million. Halyard Health had a return on equity of 6.98% and a net margin of 5.82%. The company’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.50 EPS. research analysts expect that Halyard Health Inc will post 0.96 EPS for the current fiscal year.
Several brokerages have recently issued reports on HYH. Zacks Investment Research cut Halyard Health from a “buy” rating to a “hold” rating in a research report on Thursday, February 1st. ValuEngine upgraded Halyard Health from a “hold” rating to a “buy” rating in a report on Sunday, December 31st. Finally, KeyCorp upgraded Halyard Health from a “sector weight” rating to an “overweight” rating in a report on Thursday. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Halyard Health has a consensus rating of “Buy” and a consensus price target of $49.33.
WARNING: This piece was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/09/halyard-health-inc-hyh-shares-sold-by-tiaa-cref-investment-management-llc.html.
Halyard Health Company Profile
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Want to see what other hedge funds are holding HYH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halyard Health Inc (NYSE:HYH).
Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.